0001640455-18-000039.txt : 20180312 0001640455-18-000039.hdr.sgml : 20180312 20180312190607 ACCESSION NUMBER: 0001640455-18-000039 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20180308 FILED AS OF DATE: 20180312 DATE AS OF CHANGE: 20180312 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Drapkin Kimberlee C CENTRAL INDEX KEY: 0001340881 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37998 FILM NUMBER: 18684851 MAIL ADDRESS: STREET 1: PREDIX PHARMACEUTICALS HOLDINGS, INC. STREET 2: 4 MAGUIRE ROAD CITY: LEXINGTON STATE: MA ZIP: 02421 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Jounce Therapeutics, Inc. CENTRAL INDEX KEY: 0001640455 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 454870634 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 780 MEMORIAL DRIVE CITY: CAMBRIDGE STATE: MA ZIP: 02139 BUSINESS PHONE: 857-259-3840 MAIL ADDRESS: STREET 1: 780 MEMORIAL DRIVE CITY: CAMBRIDGE STATE: MA ZIP: 02139 4 1 wf-form4_152089594368204.xml FORM 4 X0306 4 2018-03-08 0 0001640455 Jounce Therapeutics, Inc. JNCE 0001340881 Drapkin Kimberlee C C/O JOUNCE THERAPEUTICS, INC. 780 MEMORIAL DRIVE CAMBRIDGE MA 02139 0 1 0 0 CFO and Treasurer Common Stock 2018-03-08 4 M 0 3759 0.48 A 5267 D Common Stock 2018-03-08 4 S 0 5267 25.01 D 0 D Stock Option (Right to Buy) 0.48 2018-03-08 4 M 0 3759 0 D 2024-01-27 Common Stock 3759.0 3016 D The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on June 8, 2017. The Reporting Person exercised no discretion with respect to these transactions. Represents the weighted average share price of an aggregate total of 5,267 shares sold in the price range of $25.00 to $25.24 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission Staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. The option shares vested and became exercisable in 12 monthly installments from October 9, 2013. /s/ Anna L. Barry, Attorney-in-Fact 2018-03-12